Liraglutide has also been investigated in a single-centre randomized double-blind trial [82] in seventy-one patients with long-standing T2DM that measured the changes in insulin and glucagon secretion and performed magnetic resonance for the evaluation of subcutaneous, visceral and ectopic fat in the liver and pancreas; this study showed no improvement in the pancreatic fat content. Here, INS is linked to type 2 diabetes mellitus.